Volatile metabolome analysis in Inflammatory Bowel Disease
Research type
Research Study
Full title
DIAGNOSTIC ASSESSMENT OF METABOLOMIC CHANGES IN INFLAMMATORY BOWEL DISEASE
IRAS ID
197427
Contact name
Iftikhar Ahmed
Contact email
Sponsor organisation
University Hospital Southampton NHS Foundation Trust
Duration of Study in the UK
0 years, 4 months, 0 days
Research summary
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of gastrointestinal tract which affects over 600,000 people in the United Kingdom. The diagnosis and management of IBD is challenging both for patients and clinicians due to recurrent nature of the disease and complex investigations, which are invasive, expensive and unpleasant for patients. There is an ongoing need for a novel, reliable and non-invasive tool for diagnosing IBD and monitoring disease activity.\n\nMetabonomics is a new area of IBD research focusing on volatile organic metabolite analysis in various biological samples in order to diagnose IBD and differentiate it from other conditions. At present there is lack of evidence evaluating the possible relationship of volatile metabolites with diet, medications and other physiological activities, which is necessary before metabolomics data could be translated into clinical practice.\n\nWe propose a pilot study to investigate volatile metabolite profiles in stool, urine, blood and bowel tissue samples of IBD patients in order to establish whether volatile metabolite analysis could reliably differentiate different groups of patients with IBD and healthy controls. The aim of the study is to distinguish active and inactive IBD in both treatment naive and exposed patients and to investigate the relationship between volatile metabolites and dietary habits.\n\nThe study will include approximately 50 patients with new and established IBD and healthy controls. Sample collection will be undertaken at University Hospital Southampton and include blood, stool, urine and mucosal samples from IBD patients as well as stool and urine samples from healthy controls. Participants will provide information on their disease activity, location, treatment and dietary habits. Samples will be analysed using gas-chmromatography-mass spectrometry (GC-MS) at the Institute of Translational Medicine at University of Liverpool. The estimated duration of the pilot study is four months with anticipated extension into a larger research project depending on results obtained.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
16/NW/0418
Date of REC Opinion
8 Jun 2016
REC opinion
Further Information Favourable Opinion